Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 81, Issue 3, 2008, Pages 327-330

  Makino, Hisashi ^a   Okada, Sadanori ^a   Nagumo, Ayako ^a   Sugisawa, Takako ^a   Miyamoto, Yoshihiro ^a   Kishimoto, Ichiro ^a   Akie, Taura K ^b   Soma, Toshihiro ^b   Taguchi, Akihiko ^a   Yoshimasa, Yasunao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

Adiponectin; Atherosclerosis; Chronic inflammation; Endothelial progenitor cell; PPAR agonist

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE; C REACTIVE PROTEIN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

AGED; ANTIGENS, CD; ANTIGENS, CD34; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 48949091518     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.05.012     Document Type: Article

References (20)

1. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., Murayama T., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
2. Asahara T., Murohara T., and Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
3. Loomans C.J.M., de Koning E.J.P., Staal F.J.T., Rookmaaker M.B., Verseyden C., de Boer H.C., et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53 (2004) 195-199
4. + cells, myeloblasts, erythroblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 15 (2001) 3075-3085
5. Fadini G.P., de Kreutzenberg S.V., Coracina A., Baesso I., Agostini C., Tiengo A., et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur. Heart J. 27 (2006) 2247-2255
6. Taguchi A., Matsuyama T., Moriwaki H., Hayashi T., Hayashida K., Nagatsuka K., et al. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation 109 (2004) 2972-2975
7. Pistorosch F., Passauer J., and Fischer S. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
8. Esposito K., Cozzolino D., Ciotola M., Carleo D., Schisano B., Saccomanno F., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 (2006) 1071-1076
9. Blaschke F., Takata Y., Caglayan E., Law R.E., and Hsuec W.A. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arteriosc. Thromb. Vasc. Biol. 26 (2006) 28-40
10. + cells in peripheral blood of patients with cardiovascular disease. Texas Heart Inst. J. 33 (2006) 427-429
11. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J. Hematother. 5 (1996) 213-226
12. Werner C., Kamani C.H., Gensch C., Bohm M., and Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56 (2007) 2609-2615
13. + cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 114 (2004) 330-338
14. Kawamoto A., Iwasaki H., Kusano K., Murayama T., Oyamada A., Silver M., et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 114 (2006) 2163-2169
15. Yoshihara T., Taguchi A., Mastuyama T., Shimizu Y., Kikuchi-Taura A., Soma T., et al. Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J. Cereb. Blood Flow Metab. (2008) (e-Pub ahead of print January 2008)
16. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
17. Ouchi N., Ohishi M., Kihara S., Funahashi T., Nakamura T., Nagaretani H., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42 (2003) 231-234
18. Suh W., Kim L., Choi J.H., Lee Y.S., Lee J.Y., Kim J.M., et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem. Biophys. Res. Commun. 321 (2004) 65-71
19. Herbrig K., Haensel S., Oelschlaegel U., Pistrosch F., Foerster S., and Passauer J. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann. Rheum. Dis. 65 (2006) 157-163
20. Matsuo Y., Imanishi T., Kuroi A., Kitabata H., Kubo T., Hayashi Y., et al. Effects of plasma adiponectin levels on the number and function of endothelial progenitor cells in patients with coronary artery disease. Circ. J. 17 (2007) 1376-1382